{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:46:36Z","timestamp":1761489996405,"version":"build-2065373602"},"reference-count":16,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T00:00:00Z","timestamp":1462579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The association between natalizumab and progressive multifocal leukoencephalopathy (PML) is established, but a reliable clinical risk stratification flow-chart is lacking. New risk factors are needed, such as the possible role of the anti-JC polyomavirus (JCPyV) neutralizing antibody. In this pilot study, we analyzed this parameter during natalizumab treatment. Sequential sera of 38 multiple sclerosis patients during their first year of natalizumab treatment were collected, and grouped according to the number of infusions. For 11 patients, samples were also available after 24 infusions (T24), when progressive multifocal leukoencephalopathy (PML) risk is higher. The reactivity against VP1, the main JCPyV surface protein, and the anti-JCPyV neutralizing activity were evaluated. During the first year, a lack of correlation between anti-JCPyV antibody response and its neutralizing activity was observed: a significant decrease in anti-JCPyV antibody response was observed (p = 0.0039), not paralleled by a similar trend in the total anti-JCPyV neutralizing activity (p = 0.2239). This lack of correlation was even more evident at T24 when, notwithstanding a significant increase in the anti-JCPyV response (p = 0.0097), a further decrease of the neutralizing activity was observed (p = 0.0062). This is the first study evidencing, prospectively, the lack of correlation between the anti-JCPyV antibody response and its neutralizing activity during natalizumab treatment.<\/jats:p>","DOI":"10.3390\/v8050128","type":"journal-article","created":{"date-parts":[[2016,5,9]],"date-time":"2016-05-09T10:05:24Z","timestamp":1462788324000},"page":"128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7853-3224","authenticated-orcid":false,"given":"Roberta","family":"Diotti","sequence":"first","affiliation":[{"name":"Laboratorio di Microbiologia e Virologia, Universit\u00e0 \u201cVita-Salute\u201d San Raffaele, Milan 20132, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruggero","family":"Capra","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, Spedali Civili of Brescia, Brescia 25123, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Moiola","sequence":"additional","affiliation":[{"name":"Neurological Department, IRCCS Hospital San Raffaele, Milan 20132, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Caputo","sequence":"additional","affiliation":[{"name":"Laboratorio di Microbiologia e Virologia, Universit\u00e0 \u201cVita-Salute\u201d San Raffaele, Milan 20132, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"De Rossi","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Center, Spedali Civili of Brescia, Brescia 25123, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sangalli","sequence":"additional","affiliation":[{"name":"Neurological Department, IRCCS Hospital San Raffaele, Milan 20132, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Neurological Department, IRCCS Hospital San Raffaele, Milan 20132, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Burioni","sequence":"additional","affiliation":[{"name":"Laboratorio di Microbiologia e Virologia, Universit\u00e0 \u201cVita-Salute\u201d San Raffaele, Milan 20132, Italy"},{"name":"Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Clementi","sequence":"additional","affiliation":[{"name":"Laboratorio di Microbiologia e Virologia, Universit\u00e0 \u201cVita-Salute\u201d San Raffaele, Milan 20132, Italy"},{"name":"Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicasio","family":"Mancini","sequence":"additional","affiliation":[{"name":"Laboratorio di Microbiologia e Virologia, Universit\u00e0 \u201cVita-Salute\u201d San Raffaele, Milan 20132, Italy"},{"name":"Ospedale San Raffaele, Milan 20132, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2016,5,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Delbue, S., Elia, F., Carloni, C., Pecchenini, V., Franciotta, D., Gastaldi, M., Colombo, E., Signorini, L., Carluccio, S., and Bellizzi, A. (2014). JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients. J. Neurovirol.","DOI":"10.1007\/s13365-014-0268-0"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1177\/1352458514531843","article-title":"Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?","volume":"20","author":"Cutter","year":"2014","journal-title":"Mult. Scler."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3390\/v4091731","article-title":"Neutralization interfering antibodies: A \u201cnovel\u201d example of humoral immune dysfunction facilitating viral escape?","volume":"4","author":"Nicasio","year":"2012","journal-title":"Viruses"},{"key":"ref_6","first-page":"387","article-title":"New therapeutic options for HCV infection in the monoclonal antibody era","volume":"35","author":"Sautto","year":"2012","journal-title":"New Microbiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1056\/NEJMc1207116","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy","volume":"367","author":"Mancini","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.antiviral.2014.05.017","article-title":"Cloning of the first human anti-JCPyV\/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy","volume":"108","author":"Diotti","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"306ra150","DOI":"10.1126\/scitranslmed.aac8691","article-title":"Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy","volume":"7","author":"Jelcic","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"306ra151","DOI":"10.1126\/scitranslmed.aab1720","article-title":"JC polyomavirus mutants escape antibody-mediated neutralization","volume":"7","author":"Ray","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.05.009","article-title":"Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab","volume":"261","author":"Lin","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4939-0428-0_2","article-title":"Herpes simplex virus growth, preparation, and assay","volume":"1144","author":"Marconi","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1006\/viro.2001.1014","article-title":"Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs","volume":"288","author":"Burioni","year":"2001","journal-title":"Virology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11775","DOI":"10.1128\/JVI.76.22.11775-11779.2002","article-title":"Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus\/HCV pseudotype","volume":"76","author":"Burioni","year":"2002","journal-title":"J. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2012.07.013","article-title":"Anti-hepatitis C virus E2 (HCV\/E2) glycoprotein monoclonal antibodies and neutralization interference","volume":"96","author":"Sautto","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e00247-13","DOI":"10.1128\/mBio.00247-13","article-title":"Progressive multifocal leukoencephalopathy-associated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding","volume":"4","author":"Maginnis","year":"2013","journal-title":"MBio"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/5\/128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:23:30Z","timestamp":1760210610000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/8\/5\/128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,7]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5]]}},"alternative-id":["v8050128"],"URL":"https:\/\/doi.org\/10.3390\/v8050128","relation":{},"ISSN":["1999-4915"],"issn-type":[{"type":"electronic","value":"1999-4915"}],"subject":[],"published":{"date-parts":[[2016,5,7]]}}}